

Daphne Day

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1562841/publications.pdf>

Version: 2024-02-01

59
papers

1,527
citations

516710

16
h-index

345221

36
g-index

60
all docs

60
docs citations

60
times ranked

2814
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial. <i>Genome Medicine</i> , 2016, 8, 109.	8.2	211
2	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	7.0	115
3	Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities. <i>Cancer</i> , 2019, 125, 1341-1349.	4.1	115
4	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
5	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>BioDrugs</i> , 2016, 30, 571-584.	4.6	93
6	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83
7	Early phase clinical trials to identify optimal dosing and safety. <i>Molecular Oncology</i> , 2015, 9, 997-1007.	4.6	81
8	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	5.9	70
9	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016, 8, 115.	8.2	64
10	Conditional Risk of Relapse in Surveillance for Clinical Stage I Testicular Cancer. <i>European Urology</i> , 2017, 71, 120-127.	1.9	54
11	A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. <i>Oncotarget</i> , 2017, 8, 32918-32929.	1.8	46
12	An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors. , 2020, 8, e000883.		36
13	The Future of Clinical Trial Design in Oncology. <i>Cancer Discovery</i> , 2021, 11, 822-837.	9.4	32
14	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. <i>Current Oncology</i> , 2021, 28, 523-548.	2.2	31
15	Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck. <i>Cancer Treatment Reviews</i> , 2017, 54, 43-57.	7.7	28
16	COVID-19 vaccination rates, intent, and hesitancy in patients with solid organ and blood cancers: A multicenter study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 570-577.	1.1	24
17	Choice of Starting Dose for Biopharmaceuticals in First-in-Human Phase I Cancer Clinical Trials. <i>Oncologist</i> , 2015, 20, 653-659.	3.7	21
18	Cancer patients' experiences with immune checkpoint modulators: A qualitative study. <i>Cancer Medicine</i> , 2020, 9, 3015-3022.	2.8	21

#	ARTICLE	IF	CITATIONS
19	Transitions in oral and gut microbiome of HPV+ oropharyngeal squamous cell carcinoma following definitive chemoradiotherapy (ROMA LA-OPSCC study). <i>British Journal of Cancer</i> , 2021, 124, 1543-1551.	6.4	19
20	Enhanced toxicity with CDK 4/6 inhibitors and palliative radiotherapy: Non-consecutive case series and review of the literature. <i>Translational Oncology</i> , 2021, 14, 100939.	3.7	18
21	Dynamics of the cell-free DNA methylome of metastatic prostate cancer during androgen-targeting treatment. <i>Epigenomics</i> , 2020, 12, 1317-1332.	2.1	15
22	Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia. <i>Vaccines</i> , 2022, 10, 851.	4.4	15
23	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. <i>Clinical Cancer Research</i> , 2017, 23, 4980-4991.	7.0	14
24	Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy. <i>European Journal of Cancer</i> , 2019, 118, 112-120.	2.8	14
25	Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies. <i>Targeted Oncology</i> , 2021, 16, 461-469.	3.6	14
26	Long-term Surveillance of Patients with Complete Response Following Chemotherapy for Metastatic Nonseminomatous Germ Cell Tumor. <i>European Urology Oncology</i> , 2021, 4, 289-296.	5.4	13
27	Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach. <i>Canadian Urological Association Journal</i> , 2017, 12, 59-66.	0.6	12
28	Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa122.	2.9	12
29	<sc>Out-of-pocket</sc> costs associated with head and neck cancer treatment. <i>Cancer Reports</i> , 2022, 5, e1528.	1.4	10
30	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. <i>Current Oncology</i> , 2021, 28, 107-114.	2.2	10
31	Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001). <i>Investigational New Drugs</i> , 2016, 34, 575-583.	2.6	9
32	Systematic review and REMARK scoring of renal cell carcinoma prognostic circulating biomarker manuscripts. <i>PLoS ONE</i> , 2019, 14, e0222359.	2.5	9
33	Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial. <i>JCO Global Oncology</i> , 2020, 6, 585-588.	1.8	9
34	Phase II Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 334-341.	2.3	9
35	Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours. <i>BJU International</i> , 2018, 122, 814-822.	2.5	8
36	Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy. <i>Oral Oncology</i> , 2020, 105, 104666.	1.5	8

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021, 10, 5775-5782.	2.8	7
38	The PD-1/PD-L1 pathway in advanced prostate cancer—have we milked this cow?. <i>Annals of Translational Medicine</i> , 2019, 7, 346-346.	1.7	7
39	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 485-491.	3.0	5
40	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.	1.9	5
41	Association between Genetic Variants and Cisplatin-Induced Nephrotoxicity: A Genome-Wide Approach and Validation Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1233.	2.5	5
42	The Disease Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a Measure to Assess Disease-Related COVID-19 Vaccine Attitudes and Concerns. <i>Behavioral Medicine</i> , 0, , 1-10.	1.9	5
43	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	2.9	4
44	Controversies in the management of clinical stage 1 testis cancer. <i>Canadian Urological Association Journal</i> , 2020, 14, E537-E542.	0.6	4
45	Longitudinal health utility and symptom-toxicity trajectories in patients with head and neck cancers. <i>Cancer</i> , 2022, 128, 497-508.	4.1	4
46	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. <i>PLoS ONE</i> , 2021, 16, e0259272.	2.5	4
47	Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer. <i>Cancer Medicine</i> , 2022, 11, 728-734.	2.8	4
48	Atherosclerotic Cardiovascular Risk With Combination Avelumab and Axitinib. <i>Journal of Clinical Oncology</i> , 2022, 40, 3467-3469.	1.6	4
49	Systematic Review and STARD Scoring of Renal Cell Carcinoma Circulating Diagnostic Biomarker Manuscripts. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa050.	2.9	3
50	Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis. <i>Urology</i> , 2020, 138, 69-76.	1.0	3
51	A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study. <i>Targeted Oncology</i> , 2022, 17, 271-281.	3.6	3
52	Predictive radiomics signature for treatment response to nivolumab in patients with advanced renal cell carcinoma. <i>Canadian Urological Association Journal</i> , 2021, 16, .	0.6	2
53	Shrinking Hepatic Hemangiomas in a Patient Treated for Metastatic Germ Cell Tumor. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e69-e72.	1.9	1
54	Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era. <i>Oncologist</i> , 2019, 24, e518-e525.	3.7	1

#	ARTICLE	IF	CITATIONS
55	Clinical dilemmas in local and regional testis cancer. Canadian Urological Association Journal, 2020, 15, E58-E64.	0.6	1
56	Tumor- and class-specific patterns of immune-related adverse events (irAEs) of immune checkpoint inhibitors (ICIs): A systematic review (SR).. Journal of Clinical Oncology, 2016, 34, 3065-3065.	1.6	1
57	Development of a radiomic signature for predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer. Canadian Urological Association Journal, 2021, 16, .	0.6	1
58	Biomarkers of response to immune checkpoint inhibitors for metastatic castration resistant prostate cancer: looking for the needle in the haystack. Annals of Translational Medicine, 2020, 8, 894-894.	1.7	0
59	A Canadian approach to the regionalization of testis cancer: A review. Canadian Urological Association Journal, 2020, 14, 346-351.	0.6	0